CSL, uniQure hemophilia B gene therapy gets EMA panel nod for approval in EU

Dec. 16, 2022 8:57 AM ETuniQure N.V. (QURE), CSLLY, CMXHFBy: Ravikash, SA News Editor

DNA molecule

Artur Plawgo

  • A committee of the European Medicines Agency (EMA) recommended granting conditional marketing authorization to CSL (OTCPK:CSLLY) (OTCPK:CMXHF) uniQure's (NASDAQ:QURE) one-time gene therapy Hemgenix to treat severe and moderately severe Hemophilia B (congenital Factor IX

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.